https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Proteins Annexin A2 and PSA in prostate cancer biopsies do not predict biochemical failure https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33534 Wed 23 Feb 2022 16:05:22 AEDT ]]> Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29346 Wed 23 Feb 2022 16:04:41 AEDT ]]> Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: issues in model development and reporting https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25021 0.6. Shrinkage was required for all predictive models' coefficients ranging from -0.309 (prediction probability was inverse to observed proportion) to 0.823. Predictive models which include baseline symptoms as a feature produced the highest discrimination. Two models produced a predicted probability of 0 and 1 for all patients. Conclusions: Predictive models vary in performance and transferability illustrating the need for improvements in model development and reporting. Several models showed reasonable potential but efforts should be increased to improve performance. Baseline symptoms should always be considered as potential features for predictive models.]]> Wed 19 Jan 2022 15:16:35 AEDT ]]> Reduced dose posterior to prostate correlates with increased PSA progression in voxel-based analysis of 3 randomized phase 3 trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47143 Wed 14 Dec 2022 15:27:42 AEDT ]]> Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47094 Wed 14 Dec 2022 09:37:30 AEDT ]]> Metabolic, health and lifestyle profiling of breast cancer radiotherapy patients and the risk of developing fatigue https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17019 Wed 11 Apr 2018 15:14:52 AEST ]]> Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21794  9 months or TTBF > 3 years. Conclusion: TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.]]> Wed 11 Apr 2018 15:10:15 AEST ]]> Registering prostate external beam radiotherapy with a boost from high-dose-rate brachytherapy: a comparative evaluation of deformable registration algorithms https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25925 Wed 11 Apr 2018 14:57:01 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Spatial features of dose-surface maps from deformably-registered plans correlate with late gastrointestinal complications https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31828 Wed 09 Mar 2022 16:00:57 AEDT ]]> Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> Tumor innervation and clinical outcome in pancreatic cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43873 Tue 04 Oct 2022 12:29:00 AEDT ]]> Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51315 Thu 31 Aug 2023 14:30:36 AEST ]]> Accumulation of rectum dose-volume metrics for prostate external beam radiotherapy combined with brachytherapy: evaluating deformably registered dose distribution addition using parameter-based addition https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34511 0.1cc, D1cc, D2cc and D10cc were calculated in two ways. (i) Parameter-adding: the EBRT DVH parameters (or the EBRT prescription dose) were added to the unregistered HDR-BT DVH parameters. (ii) Distribution-adding: the parameters were extracted after the EBRT doses were 3D-summed with the registered HDR-BT doses. Resulting differences between the parameters were investigated. Results: The D0.1cc, D1cc and D2cc from parameter-adding were 21.3% (P < 0.001), 6.3% (P < 0.001) and 3.5% (P < 0.001) smaller than those from distribution-adding. The D10cc was 2.2% (P=0.015) larger for distribution-adding. Conclusion: Distribution-adding was confounded by unsystematic inter/intra-observer rectum-contouring errors and registration accuracy near the anterior rectal wall. Consequently, clinical use of distribution-adding to assess rectal doses requires careful contour and registration evaluation.]]> Thu 28 Oct 2021 13:04:40 AEDT ]]> Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46465 n=388) and CHHiP (n=241) trials onto the same exemplar and repeating the tests on each of these data sets, and on all three datasets combined. Results: Voxel-based Cox regression and permutation dose difference testing revealed regions where increased dose was correlated with gastrointestinal toxicity. Grade=2 RB was associated with posteriorly extended lateral beams that manifested high doses (> 55 Gy) in a small rectal volume adjacent to the clinical target volume. A correlation was found between grade=2 tenesmus and increased low-intermediate dose (~25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). Conclusions: The serial response of the rectum with respect to RB has been demonstrated in patients with posteriorly extended lateral beams. Similarly, the parallel response of the PRFS with respect to tenesmus has been demonstrated in patients treated with the posterior beam.]]> Thu 24 Nov 2022 15:46:42 AEDT ]]> Increased dose to organs in urinary tract associates with measures of genitourinary toxicity in pooled voxel-based analysis of 3 randomized phase III trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40019 n = 388) and CHHiP (up to n = 247) trials onto the same exemplar and repeating the voxel-based tests on each of these data sets. All three datasets were then combined, and the tests repeated. Results: Voxel-based Cox regression and multiple comparison permutation dose difference testing revealed regions where increased dose was correlated with genitourinary toxicity. Increased dose in the vicinity of the membranous and spongy urethra was associated with dysuria for all datasets. Haematuria was similarly correlated with increased dose at the membranous and spongy urethra, for the RADAR, CHHiP, and combined datasets. Some evidence was found for the association between incontinence and increased dose at the internal and external urethral sphincter for RADAR and the internal sphincter alone for the combined dataset. Incontinence was also strongly correlated with dose from posterior oblique beams. Patients with fields extending inferiorly and posteriorly to the CTV, adjacent to the membranous and spongy urethra, were found to experience increased frequency. Conclusions: Anatomically-localized dose-toxicity relationships were determined for late genitourinary symptoms in the urethra and urinary sphincters. Low-intermediate doses to the extraprostatic urethra were associated with risk of late dysuria and haematuria, while dose to the urinary sphincters was associated with incontinence.]]> Thu 14 Jul 2022 13:55:37 AEST ]]> External validation of a predictive model of urethral strictures for prostate patients treated with HDR Brachytherapy boost https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37248 50 = 116.7 Gy and m = 0.23; n was fixed to 0.3, based on numerical optimization of the likelihood. The calibration plot showed a good agreement between the observed toxicity and the probability predicted by the model, confirmed by bootstrapping. For the external validation, the calibration plot showed that the observed toxicity obtained with the RADAR patients was well-represented by the fitted LKB model parameters. When patients were stratified by the use of AD TD50 decreased when AD was not present. Conclusions: Lyman–Kutcher–Burman model parameters were fitted to the risk of urethral stricture and externally validated with an independent cohort, to provide guidance on urethral tolerance doses for patients treated with a HDRB boost. For patients that did not receive AD, model fitting provided a lower TD50 suggesting a protective effect on urethra toxicity.]]> Thu 09 Dec 2021 11:03:03 AEDT ]]> Modeling urinary dysfunction after external beam radiation therapy of the prostate using bladder dose-surface maps: evidence of spatially variable response of the bladder surface https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34316 Thu 03 Feb 2022 12:21:50 AEDT ]]> Multi-atlas and unsupervised learning approach to perirectal space segmentation in CT images https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29560 Thu 03 Feb 2022 12:21:46 AEDT ]]> Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32780 Thu 03 Feb 2022 12:18:11 AEDT ]]> Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7893 Sat 24 Mar 2018 10:44:59 AEDT ]]> PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7230 Sat 24 Mar 2018 08:40:27 AEDT ]]> Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7789 Sat 24 Mar 2018 08:39:20 AEDT ]]> Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7041 Sat 24 Mar 2018 08:37:55 AEDT ]]> Thrombin generation as a predictor of radiotherapy induced skin erythema https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8029 Sat 24 Mar 2018 08:36:48 AEDT ]]> Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> Assuring high quality treatment delivery in clinical trials: results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7330 Sat 24 Mar 2018 08:35:12 AEDT ]]> Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer?: a prospective study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7132 Sat 24 Mar 2018 08:34:18 AEDT ]]> The radiotherapeutic injury: a complex 'wound' https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1464 Sat 24 Mar 2018 08:28:05 AEDT ]]> MRI-guided prostate radiation therapy planning: investigation of dosimetric accuracy of MRI-based dose planning https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12469 Sat 24 Mar 2018 08:16:30 AEDT ]]> Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13279 Sat 24 Mar 2018 08:15:16 AEDT ]]> It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10956 Sat 24 Mar 2018 08:14:14 AEDT ]]> Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy?: assessment with cone-beam computerised tomography scans https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12323 Sat 24 Mar 2018 08:11:36 AEDT ]]> A methodology for the analysis of PSA response signatures https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12305 Sat 24 Mar 2018 08:11:35 AEDT ]]> Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10469 Sat 24 Mar 2018 08:09:12 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18210 Sat 24 Mar 2018 08:04:37 AEDT ]]> A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18126 Sat 24 Mar 2018 08:04:29 AEDT ]]> Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18127 Sat 24 Mar 2018 08:04:29 AEDT ]]> Radiation induced bowel injury: a neglected problem https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17298 Sat 24 Mar 2018 08:01:46 AEDT ]]> Researching depression in prostate cancer patients: factors, timing, and measures https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17349 Sat 24 Mar 2018 08:01:41 AEDT ]]> Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20745 Sat 24 Mar 2018 08:00:23 AEDT ]]> Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20769 Sat 24 Mar 2018 08:00:21 AEDT ]]> Direct dose to water dosimetry for pretreatment IMRT verification using a modified EPID https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17704 Sat 24 Mar 2018 07:57:30 AEDT ]]> A magnetic resonance imaging-based workflow for planning radiation therapy for prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17685 Sat 24 Mar 2018 07:57:27 AEDT ]]> Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17874 Sat 24 Mar 2018 07:56:44 AEDT ]]> Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20690 Sat 24 Mar 2018 07:55:40 AEDT ]]> Radiation enteropathy - pathogenesis, treatment and prevention https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21279 Sat 24 Mar 2018 07:54:41 AEDT ]]> Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: analysis of data from the radar prostate radiation therapy trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21106 Sat 24 Mar 2018 07:53:59 AEDT ]]> Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20180 Sat 24 Mar 2018 07:51:39 AEDT ]]> Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18511 Sat 24 Mar 2018 07:50:08 AEDT ]]> Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5594 Sat 24 Mar 2018 07:49:21 AEDT ]]> Hypofractionated versus standard fractionation radiotherapy in early glottic cancer: a retrospective review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5009 Sat 24 Mar 2018 07:44:12 AEDT ]]> MRI simulation: end-to-end testing for prostate radiation therapy using geometric pelvic MRI phantoms https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27970 Sat 24 Mar 2018 07:38:43 AEDT ]]> The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28140 Sat 24 Mar 2018 07:36:38 AEDT ]]> Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26791 Sat 24 Mar 2018 07:36:30 AEDT ]]> Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26054 Sat 24 Mar 2018 07:31:34 AEDT ]]> Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23364 0.5 ng/mL) alone and when assessed in conjunction with the randomised treatment group increased risk of PCSM in the US trial (PSA nadir p=0.0016; PSA end p=0.017) and Australasian trial (PSA nadir p<0.0001; PSA end p=0.0012). In both trials, the randomised treatment group was no longer associated with PCSM (p>=0.20) when the candidate surrogates were included in the model. Therefore, both PSA metrics satisfied Prentice criteria for surrogacy. INTERPRETATION: After radiotherapy and 6 months of androgen suppression, men with PSA end values exceeding 0.5 ng/mL should be considered for long-term androgen suppression and those with localised or locally advanced prostate cancer with PSA nadir values exceeding 0.5 ng/mL should be considered for inclusion in randomised trials investigating the use of drugs that have extended survival in castration-resistant metastatic prostate cancer.]]> Sat 24 Mar 2018 07:16:30 AEDT ]]> Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> When to choose radiotherapy for prostate cancer, and what technique? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23004 Sat 24 Mar 2018 07:15:43 AEDT ]]> Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22558 Sat 24 Mar 2018 07:14:46 AEDT ]]> Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: a comparison of conventional and machine-learning methods https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24849 0.6 while all haematuria endpoints and longitudinal incontinence models produced AUROC<0.6. Conclusions: Logistic regression and MARS were most likely to be the best-performing strategy for the prediction of urinary symptoms with elastic-net and random forest producing competitive results. The predictive power of the models was modest and endpoint-dependent. New features, including spatial dose maps, may be necessary to achieve better models.]]> Sat 24 Mar 2018 07:11:24 AEDT ]]> "Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22209 Sat 24 Mar 2018 07:11:17 AEDT ]]> High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51755 Mon 18 Sep 2023 14:16:17 AEST ]]> Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41992 Mon 10 Jul 2023 11:24:21 AEST ]]> Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42619 Mon 04 Sep 2023 13:58:46 AEST ]]> Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42994 Fri 09 Sep 2022 14:03:28 AEST ]]> Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49118 Fri 05 May 2023 11:46:16 AEST ]]> Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34625 a sense of control over the things that happen to oneself. Implications for treatment models of psychosocial oncology support for PCa survivors are discussed.]]> Fri 05 Apr 2019 11:34:02 AEDT ]]> Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32124 Fri 04 May 2018 10:39:30 AEST ]]>